BCAB

BioAtla Inc.

Price

$1.71

return (12m)

-94.50%

p/e

-0.09

p/bv

-0.08

DIVIDEND YIELD

0.00%

BCAB price

BioAtla

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment BCAB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-50.43%

3 months

-52.76%

1 year

-94.50%

2 years

-98.01%

5 years

-99.89%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals BCAB

Valuation

P/E

-0.09

Sector -3.50

Industry -3.50

P/BV

-0.08

Sector 2.02

Industry 2.02

P/Revenue (PSR)

0.46

Sector 2.01

Industry 2.01

EV/EBITDA

6.29

Sector -214.99

Industry -214.99

EV/EBIT

6.29

Sector -47.59

Industry -47.59

P/EBITDA

-0.09

Sector -21.41

Industry -21.41

P/EBIT

-0.09

Sector -28.65

Industry -28.65

P/Total Assets

0.31

Sector 1.19

Industry 1.19

P/Net Current Assets

-0.07

Sector -11.97

Industry -11.97

P/Working Capital

-0.18

Sector -167.95

Industry -167.95

EPS

-18.94

Sector -1.81

Industry -1.81

BVPS

-21.82

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

100.00%

Sector 41.30%

Industry 41.30%

EBITDA Margin

3.49%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

3.49%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

-100.00%

Sector -35.21%

Industry -35.21%

Net Profit Margins

-100.00%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.68

Sector 0.02

Industry 0.02

Profitability

ROE

86.80%

Sector -56.04%

Industry -56.04%

ROA

-330.89%

Sector -60.31%

Industry -60.31%

ROIC

13.11%

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

0.20

Sector 2.89

Industry 2.89

Net Debt / EBITDA

-6.80

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

-6.80

Sector -8.06

Industry -8.06

Net Debt / Equity

0.04

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.00

Sector -0.85

Industry -0.85

Equity/Assets

-3.81

Sector 0.46

Industry 0.46

Liabilities/Assets

4.81

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

91.86%

Sector -

Industry -

5Y Earnings CAGR

-19.90%

Sector -

Industry -

Fundamentals BCAB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
BCAB BioAtla Inc.	$1.71	-94.50%	0.00%	-0.09	-0.08	86.80%	-100.00%
JNJ Johnson & Johnson	$269.99	56.71%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.66	23.21%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.96	22.44%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.24	-26.07%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.87	87.26%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.08	10.74%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$63.06	48.20%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$71.40	-50.11%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$385.65	38.85%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.85	33.10%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$112.45	44.52%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.65	25.89%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$508.34	32.68%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$225.38	52.58%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$990.32	34.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.02	29.13%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

BCAB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT BioAtla

BioAtla Inc.

Average Investor10 user rating

4.0 (1 people)

United States

19 years

Founded: 2007

2020

Time since IPO - 6 years

36

Employees

BioAtla Inc. (United States) is listed on the Nasdaq and has a market capitalization of $2.97 million, with shareholders equity totaling $-36.24 million.

The company employs approximately 36 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, BioAtla Inc. reported $6.50 million in revenue, generating net income of $-31.45 million.

Key financial metrics include a P/E ratio of -0.09, a price-to-book (P/B) ratio of -0.08, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker BCAB.

Market cap

$2.97 million

Net worth

$-36.24 million

$-36,236,000.00

Assets

$9.51 million

$9,506,000.00

Total Shares Outstanding

1.66 million

1,660,000

Average Daily Trading Volume

$74.52 Thousand

$74,520.18

Sector

Health Care

Industry

Biotechnology

BCAB

BCAB revenue and profits

Financial Results BCAB

DRAG THE FRAME TO SEE MORE DATA

BCAB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.65 25,89% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$225.38 52,58% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.99 56,71% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.96 22,44% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.87 87,26% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.08 9,00% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.66 23,21% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.65 25,89% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$225.38 52,58% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.99 56,71% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.96 22,44% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.87 87,26% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.08 9,00% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.66 23,21% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of BioAtla (BCAB) today?

A cotação de BioAtla (BCAB) hoje está em US$ 1.71, com uma variação de -94.5% em relação ao último ano. A cotação de BioAtla (BCAB) iniciou o ano negociando na casa dos US$ 0.57 e hoje está em US$ 1.71. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de BioAtla (BCAB) e dados de ações do Ibovespa e mercados internacionais.

Quando BioAtla (BCAB) paga dividendos?

BioAtla (BCAB) não distribuiu dividendos no último ano.

Is BioAtla (BCAB) a good investment?

Atualmente, BioAtla (BCAB) está cotada a US$ 1.71, com um P/L de -0.09, representando um desvio de -111% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de -94.5 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de -94.50%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy BioAtla (BCAB) stock?

Investir em ações de BioAtla (BCAB) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of BioAtla (BCAB) yield today?

A rentabilidade de BioAtla (BCAB) foi de -50.43% no último mês, -94.50% no último ano e -99.89% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de BioAtla (BCAB) hoje, o investimento total seria de US$ 171.00, com base na cotação atual de US$ 1.71.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 9.41
Em 5 anos: US$ 0.19
Em 10 anos: US$ 171.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

BCAB

BioAtla Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment BCAB

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING BCAB WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT BioAtla

BioAtla Inc.

United States

19 years

2020

36

PROFIT X PRICE BCAB

Financial Results BCAB

BCAB cash flow

Asset, Revenue and Profit Growth - BCAB

BCAB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions